Published in Lab Law Weekly, December 15th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Acusphere.
Report 1: Acusphere, Inc., (ACUS) has trained all of the echo blinded readers in the RAMP-2 trial to increase their sensitivity, the ability to detect coronary heart disease, in stress echo images enhanced by its lead product candidate, Imagify (formerly known as AI-700).
In connection with this training, all RAMP-2 echo blinded readers read with higher sensitivity than prior to the training, while maintaining high accuracy, the ability to correctly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.